Initiated by the WHO study, associated with the use of cannabis for medical purposes
Expert Committee on Drug Dependence (ECDD), the World Health Organization (WOG) plans to prepare the ground for a decision on the possibility of the use of psychoactive hemp beznarkoticheskih and components for medical purposes.
Expert Committee on Drug Dependence (Expert Committee on Drug Dependence, ECDD) World Health Organization (WHO) initiated the first steps to study issues related with the use of psychoactive cannabis in the medical field. ECDD made a commitment to hold a special meeting on the subject. Over the next fifteen years, the Committee plans to first ask the countries belonging to the WHO, and further explore the resulting worldwide information regarding experience in the use of extracts and tinctures tetrahydrocannabinol, cannabidiol and other cannabinoids stereoisomers or members of the hemp.
After painstaking study obtained data ECDD plans to prepare a framework for decision-making about the possibility of the use of psychoactive hemp beznarkoticheskih and components for medical purposes. In addition, prepared by experts of the Committee review will be the first since 1935 scientific document / guidance on the use of psychoactive hemp prepared the structure of the United Nations.
Comment of the Association "Ukrainian industrial hemp"
Such expert analysis conducted by the Committee on Drug Dependence will be held for the first time since 1935 - the moment when the cannabis of Health Committee of the League of Nations has been classified as "particularly dangerous drugs, turnover of which is prohibited."
At the 37th session of the WHO secretariat suggested ECDD start collecting data relating to the question related to the possibility of the use of cannabis, cannabis resin, extracts and tinctures of cannabis for medical purposes, for the consideration of the information received at the next meeting of the Committee. Based on the prepared requests for review of the scientific literature to those skilled sample was prepared by the Committee relating to the question under study. After discussion, the representatives of the Committee pointed out that at the moment, cannabis, cannabis resin, extracts and tinctures of cannabis are included in Table I of the Single Convention on Narcotic Drugs of 1961 (the Convention). In addition, cannabis and cannabis resin are also found in Schedule IV of the Convention. The Committee's report states that there are natural and synthetic cannabinoids that are included in Schedules I and II of the 1972 Convention.
The Committee acknowledges:
- Increasing use of cannabis and its various components for medical purposes;
- The emergence of new cannabis medicines associated with the therapeutic use of cannabis;
- That the psychoactive cannabis has never been the subject of study ECDD professionals.
According to the results of the negotiations, the Committee requested the WHO Secretariat to prepare the relevant documentation for the WHO on the basis of the preliminary reports on the following topics related to cannabis:
- Cannabis plant and cannabis resin;
- Extracts and tinctures of cannabis;
- Delta-9-tetrahydrocannabinol (THC);
Information taken from the site http://tku.org.ua